Glytec said the US Patent and Trademark Office (USPTO) has issued two more patent allowances for Glytec’s FDA-cleared proprietary software used by healthcare providers to guide the dosing of insulin.
“The allowances, which comprise a combined total of 52 claims, cite systems and methods specific to subcutaneous basal and bolus insulin,” said Glytec.
“To date, Glytec has amassed an intellectual property portfolio of 18 issued or allowed patents for its eGlycemic Management System and has several dozen patents pending.”
Glytec’s Chief Medical Officer Andrew Rhinehart said: “The proposed CMS quality measure for severe hypoglycemia further underscores the gravity of this problem.
“It’s exciting to see the groundswell of support the measure is getting from all sectors of the healthcare industry.”